Results 91 to 100 of about 25,219 (211)

Self‐poisoning with 60 tablets of Apixaban, a pharmacokinetics case report [PDF]

, 2018
Bénédicte Franck, Sylvain Dulaurent, Souleiman El Balkhi, Caroline Monchaud, Nicolas Picard, Sylvain Couderc, Pierre Marquet, Franck Saint‐Marcoux, Jean‐Baptiste Woillard   +8 more
openalex   +1 more source

Extended treatment for venous thromboembolism: Is direct oral anticoagulant dose‐reduction better for all?

HemaSphere, Volume 10, Issue 3, March 2026.
Mandy N. Lauw, Saskia Middeldorp, Marc Carrier   +2 more
wiley   +1 more source

Cost-effectiveness of Apixaban versus Warfarin and Aspirin in Sweden for Stroke Prevention in Patients with Atrial Fibrillation [PDF]

, 2014
Tereza Lanitis, Thitima Kongnakorn, Lena Jacobson, Anna De Geer   +3 more
openalex   +1 more source

Apixaban versus enoxaparin to prevent venous thromboembolism in post-operative patients with gynecologic cancers at an urban academic medical center

Gynecologic Oncology Reports
Objective: A recent clinical trial demonstrated that the use of apixaban was safe and equal to enoxaparin (LMWH) in post-operative gynecologic oncology patients.
Victoria Diamond, Katherine Gerber, Geno Merli, Rebecca Mercier, Aaron Shafer, Norman Rosenblum   +5 more
doaj   +1 more source

Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation

, 2015
Hiroyuki Osanai, Masayoshi Ajioka, Tomohiro Masutomi, Tasuku Kuwayama, Sota Ishihama, Yusuke Sakamato, Naoya Otaka, Teruhiro Sakaguchi, Yosuke Inoue, Takahiro Kanbara, Yoshihito Nakashima, Hiroshi Asano, Kazuyoshi Sakai   +12 more
openalex   +2 more sources

Apixaban-induced cutaneous hypersensitivity: a case series with evidence of cross-reactivity [PDF]

, 2020
Nasro A. Isaq, Whitney M Vinson, Sahand Rahnama‐Moghadam   +2 more
openalex   +1 more source

Dependence of clot structure and fibrinolysis on apixaban and clotting activator

Research and Practice in Thrombosis and Haemostasis
Background: Anticoagulants prevent the formation of potentially fatal blood clots. Apixaban is a direct oral anticoagulant that inhibits factor (F)Xa, thereby impeding the conversion of prothrombin into thrombin and the formation of blood clots.
Rebecca A. Risman, Mitali Shroff, Julie Goswami, Valerie Tutwiler   +3 more
doaj   +1 more source

Correction to: Prevalence and factors associated with inappropriate dosing of apixaban and rivaroxaban in hospitalized older adults with atrial fibrillation: a cross‑sectional study [PDF]

, 2023
Théodore Decaix, Kenza Kemache, Pierre Gay, Olivier Laprévôte, Flora Ketz, Éric Pautas   +5 more
openalex   +1 more source

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence

Drug Design, Development and Therapy, 2014
Ali Zalpour,1 Thein Hlaing Oo21Division of Pharmacy – Clinical Programs, 2Section of Thrombosis and Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAAbstract: Anticoagulation with heparin and vitamin K ...
Zalpour A, Oo TH
doaj  

Apixaban plasma concentrations before and after catheter ablation for atrial fibrillation.

PLoS ONE
BackgroundCatheter ablation in patients with atrial fibrillation is associated with a transient increase in thromboembolic risk and adequate anticoagulation is highly important.
Rachel Aakerøy, Jan Pål Loennechen, Roar Dyrkorn, Stian Lydersen, Arne Helland, Olav Spigset   +5 more
doaj   +1 more source